Tonix Pharmaceuticals Holding Corp. TNXP

Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for TONMYA (cyclobenzaprine HCl sublingual tablets), effective immediately, adding about 21 million Medicare lives (38% of the U.S. total of ~55 million). Medicare coverage now totals 32 million lives (58%). Commercial and government payer coverage for TONMYA now covers roughly 166 million lives (53% of ~314 million total U.S. lives). TONMYA was approved for fibromyalgia in adults on Aug. 15, 2025, and is covered by Medicaid in nearly all states. The company previously disclosed commercial payer agreements with two group purchasing organizations and one major managed Medicare agreement. About 50 new sales reps have been activated, bringing the field to 150. The leadership frames TONMYA as a first-in-class, non-opioid bedtime treatment with potential to expand access and awareness. Significant expansion of payer coverage and increased sales force could materially boost TONMYA's market access and future revenue potential.

Tonix Pharmaceuticals targets TONMYA growth while advancing a Lyme prevention trial. Nearing Lyme prevention trial and TONMYA growth targets represent major pipeline progress that can significantly shift company trajectory and investor views.

Tonix Pharmaceuticals Holding Corp. reports $11.0 million in Tonmya net revenue for 2Q26. Reported net revenue from Tonmya directly reflects product sales performance and near-term financial results.

Tonix Pharmaceuticals reports TONMYA sales surge and advances Lyme disease and depression pipeline. TONMYA sales surge boosts near-term revenue while Lyme and depression pipeline progress signals major long-term growth potential.

Tonix Pharmaceuticals (TNXP) held its Q2 2026 earnings call. Q2 2026 earnings call provides financial results and outlook that may affect TNXP stock.

Tonix Pharmaceuticals Holding Corp reports Q2 2026 earnings call highlights with TONMYA showing a surge. TONMYA surge in Q2 2026 earnings signals major product momentum that can shift TNXP trajectory and investor views.

Tonix Pharmaceuticals reported Q2 financial results in an earnings call covering revenue, losses, pipeline progress and cash position. Q2 earnings call updates financial performance and pipeline status that may shift near-term sentiment but not alter long-term trajectory.

Tonix Pharmaceuticals obtained positive minutes from a Type C FDA meeting regarding its adaptive Phase 2 field study of TNX-4800, a human anti-OspA monoclonal antibody to prevent Lyme disease in the U.S. Positive FDA feedback advances TNX-4800 Phase 2 development and strengthens Tonix pipeline prospects in Lyme prevention.

Tonix Pharmaceuticals Holding Corp. announces major managed Medicare payer agreement for TONMYA®. Major Medicare payer agreement expands TONMYA® access and revenue potential.

Tonix Pharmaceuticals secured a new payer agreement expanding Medicare coverage for TONMYA. New Medicare coverage agreement for TONMYA improves product access and potential revenue.

Tonix Pharmaceuticals enrolls first patient in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder treatment. Phase 2 initiation for new MDD indication advances pipeline with moderate potential effects on future performance.

Tonix Pharmaceuticals secured its second commercial payer agreement for TONMYA, expanding total commercial coverage to ~52 million U.S. lives. Expanded payer coverage to 52 million lives materially improves TONMYA market access and revenue potential.

TNXP stock rises following company announcements on pipeline progress and potential catalysts in development programs. Announcement-driven moves affect near-term sentiment without fundamentally shifting company trajectory.

Tonix Pharmaceuticals secures commercial payer coverage for Tonmya to provide access for about 35 million U.S. patients. Expanded payer coverage for Tonmya broadens patient access and supports higher future revenue for TNXP.

Tonix Pharmaceuticals Holding Corp. (TNXP) reported first quarter 2026 financial results and operational highlights. Quarterly financial results and operational highlights affect financial performance and market sentiment but are routine disclosures.

Tonix Pharmaceuticals secures commercial payer coverage for TONMYA, providing access for approximately 35 million U.S. patients. Payer coverage for TONMYA expands patient access to 35 million, significantly boosting revenue potential and investor sentiment.

Tonix Pharmaceuticals presents Phase 1 data and announces plans for an Adaptive Phase 2 Field Study of TNX-4800, an anti-Borrelia OspA monoclonal antibody for preventing Lyme Disease, at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University. Pipeline advancement to Phase 2 for Lyme Disease prevention monoclonal antibody signals major strategic progress with high potential to boost investor sentiment and alter TNXP's biotech trajectory.

Tonix Pharmaceuticals announces publication of steady-state pharmacokinetics of TONMYA® after 20 days of daily dosing in Clinical Pharmacology in Drug Development. Peer-reviewed PK data publication supports TONMYA development and may boost investor sentiment but lacks transformative clinical or regulatory outcomes.

Tonix Pharmaceuticals presents Phase 1 data and outlines planned Adaptive Phase 2 Field Study of TNX-4800 for Lyme Disease prevention at World Vaccine Congress Washington 2026. Phase 1 data presentation and Phase 2 study plans advance TNXP's pipeline in the Lyme Disease market but remain early-stage without definitive efficacy results.

Tonix Pharmaceuticals dosed the first participant in a Phase 1 investigator-initiated pharmacodynamic study of TNX-1900 (intranasal potentiated oxytocin) to assess potential for treating migraine and craniofacial pain. Phase 1 study initiation advances TNXP's pipeline into migraine market but limited by early stage and investigator-led design.

Tonix Pharmaceuticals Holding Corp. (TNXP) reports approximately 2500 patients have initiated treatment with Tonmya following its November 2025 commercial launch. Rapid uptake of 2500 patients on Tonmya post-launch signals strong commercial success and potential revenue acceleration for TNXP.

Tonix Pharmaceuticals Holding Corp. (TNXP) reported fourth quarter and full year 2025 financial results alongside operational highlights. Annual financial results and operational updates represent major disclosures that can drive substantial shifts in market performance and investor outlook.

Tonix Pharmaceuticals presented post hoc analyses of Phase 3 data on TONMYA™ at the 8th International Congress on Controversies in Fibromyalgia. Post hoc Phase 3 data presentation on TONMYA at a fibromyalgia congress moderately influences investor sentiment and drug development positioning.

Tonix Pharmaceuticals presented data on TONMYA™ for treating fibromyalgia patients at the 2026 AAPM PainConnect Annual Meeting. Presenting clinical data on a key fibromyalgia drug candidate at a major pain medicine conference may boost market sentiment and highlight product progress.

Tonix Pharmaceuticals presented data on TONMYA in treating fibromyalgia patients at the 2026 AAPM PainConnect Annual Meeting. Presentation of fibromyalgia treatment data on TONMYA at a major pain meeting could moderately influence investor sentiment and TNXP's clinical pipeline perception.

Tonix Pharmaceuticals announces publication of clinical pharmacokinetic studies of TONMYA™ and prototype formulations in the Journal Clinical Pharmacology in Drug Development. Publication of pharmacokinetic studies advances TONMYA™ development and supports regulatory progress but lacks transformative clinical or approval outcomes.

Tonix Pharmaceuticals Holding Corp. (TNXP) announces uplisting from Nasdaq Capital Market to Nasdaq Global Select Market, meeting stringent listing requirements including minimum market value and financial standards. Uplisting to Nasdaq Global Select Market boosts visibility, liquidity, institutional investor access, and financing prospects, significantly enhancing TNXP's market performance and trajectory.

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (Cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit, highlighting the drug's potential in treating fibromyalgia and chronic pain without the risks associated with opioids. The presentation of Phase 3 data could significantly influence investor sentiment and the company's market position in the non-opioid pain management sector.

Tonix Pharmaceuticals Holding Corp. (TNXP) has been highlighted in Zacks Small Cap Research's best ideas for 2026, indicating a positive outlook for the company. The report emphasizes TNXP's innovative approaches and potential growth in the pharmaceutical sector, particularly in developing treatments for various conditions. Investors are encouraged to consider TNXP as a promising opportunity in the small-cap market, reflecting confidence in its strategic direction and product pipeline. The recognition in a best ideas report suggests significant potential for future growth and investor interest.

Tonix Pharmaceuticals Holding Corp. has priced a registered direct offering of 615,025 shares at $16.26 each, aiming to raise approximately $10 million. The offering is expected to close on or about October 30, 2023, with proceeds intended for general corporate purposes, including funding clinical trials and other operational expenses. The share offering may provide necessary funding for clinical trials, impacting financial performance and operational capabilities.